Center for Scientific Review Notice of Closed Meetings, 73491 [2020-25454]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 85, No. 223 / Wednesday, November 18, 2020 / Notices
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NIDDK Technology
Advancement Office December 3, 2020
will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Betty B. Tong, Ph.D., Senior
Licensing and Patenting Manager,
NIDDK Technology Advancement
Office, Telephone: 301–451–7836;
Email: tongb@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to SLU:
1. U.S. Provisional Patent Application
No. 62/877,385, filed July 23, 2019,
entitled ‘‘Treatment And Prevention
Of Neuropathic Pain With P2Y14
Antagonists’’ (HHS Ref. No. E–144–
2019–0–US–01)
2. U.S. Provisional Patent Application
No. 63/013,792, filed April 22, 2020,
entitled ‘‘Treatment And Prevention
Of Neuropathic Pain With P2Y14
Antagonists’’ (HHS Ref. No. E–144–
2019–1–US–01)
3. U.S. Patent Application 16/936,951,
filed July 23, 2020, entitled
‘‘Treatment And Prevention Of
Neuropathic Pain With P2Y14
Antagonists’’ [HHS Ref. No. E–144–
2019–2–US–01]
The patent rights in these inventions
have been assigned to the Government
of the United States of America, and
Saint Louis University. The prospective
patent license will be for the purpose of
consolidating the patent rights to SLU,
co-owner of said rights, for commercial
development and marketing.
Consolidation of these co-owned rights
is intended to expedite development of
the invention, consistent with the goals
of the Bayh-Dole Act codified as 35
U.S.C. 200–212. The prospective patent
license will be worldwide, exclusive,
and may be limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by SLU will be
subject to the provisions of 37 CFR part
401 and 404.
The invention pertains to methods for
treating and preventing neuropathic
pain by using selective antagonists for
the P2Y14 receptor, a purinergic G
protein-coupled receptor that is
activated by extracellular UDP-glucose
and related nucleotides. The technology
provides a method of treating
VerDate Sep<11>2014
17:59 Nov 17, 2020
Jkt 253001
neuropathic pain by administering a
P2Y14 receptor antagonist comprising a
naphthalene or phenyl-triazolyl
scaffold, potentially increase efficacy of
treatments for neuropathic pain, and
minimize risk of addiction.
This notice is made pursuant to 35
U.S.C. 209 and 37 CFR part 404. The
prospective exclusive patent license
will include terms for the sharing of
royalty income with NIDDK from
commercial sublicenses of the patent
rights and may be granted unless within
fifteen (15) days from the date of this
published notice the NIDDK receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available. License applications
submitted in response to this Notice
will be presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: November 12, 2020.
Charles D. Niebylski,
Director, Technology Advancement Office,
National Institute of Diabetes and Digestive
and Kidney Diseases.
[FR Doc. 2020–25455 Filed 11–17–20; 8:45 am]
BILLING CODE 4140–01–P
73491
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Population Science and
Epidemiology–B.
Date: December 8, 2020.
Time: 10:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Gianina Ramona
Dumitrescu, Ph.D., MPH, Scientific Review
Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4193–C, Bethesda, MD 28092,
dumitrescurg@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Electronic Nicotine Delivery Systems—Basic
Mechanisms of Health Effects.
Date: December 17–18, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ghenima Dirami, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4122,
MSC 7814, Bethesda, MD 20892, (240) 498–
7546, diramig@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 13, 2020.
Patricia B. Hansberger,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2020–25454 Filed 11–17–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HOMELAND
SECURITY
National Institutes of Health
Coast Guard
Center for Scientific Review Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
[Docket Number USCG–2020–0667]
Offshore Patrol Cutter Acquisition
Program; Preparation of a
Programmatic Environmental Impact
Statement/Overseas Environmental
Impact Statement
Coast Guard, DHS.
Notice of intent to prepare a
Programmatic Environmental Impact
Statement (PEIS)/Overseas
Environmental Impact Statement
(POEIS); request for comments.
AGENCY:
ACTION:
E:\FR\FM\18NON1.SGM
18NON1
]]>Agencies
[Federal Register Volume 85, Number 223 (Wednesday, November 18, 2020)]
[Notices]
[Page 73491]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25454]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Population Science and Epidemiology-B.
Date: December 8, 2020.
Time: 10:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Gianina Ramona Dumitrescu, Ph.D., MPH,
Scientific Review Officer, Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive, Room 4193-C, Bethesda,
MD 28092, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Electronic Nicotine Delivery Systems--Basic
Mechanisms of Health Effects.
Date: December 17-18, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ghenima Dirami, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4122, MSC 7814, Bethesda, MD
20892, (240) 498-7546, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: November 13, 2020.
Patricia B. Hansberger,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2020-25454 Filed 11-17-20; 8:45 am]
BILLING CODE 4140-01-P
